Compare CSTM & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | TARS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | France | United States |
| Employees | 11500 | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2012 | 2020 |
| Metric | CSTM | TARS |
|---|---|---|
| Price | $34.55 | $65.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $30.75 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.1M | 595.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 405.26 | 48.21 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $8,449,000,000.00 | $451,360,000.00 |
| Revenue This Year | $21.46 | $56.43 |
| Revenue Next Year | $0.50 | $30.19 |
| P/E Ratio | $23.51 | ★ N/A |
| Revenue Growth | 15.19 | ★ 146.71 |
| 52 Week Low | $11.60 | $38.51 |
| 52 Week High | $34.35 | $85.25 |
| Indicator | CSTM | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 51.22 |
| Support Level | $14.04 | $61.24 |
| Resistance Level | N/A | $67.24 |
| Average True Range (ATR) | 1.33 | 3.59 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 98.71 | 81.30 |
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.